An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

OJEMDA®

Drug Information Related Patent

Hold Company

DAY ONE BIOPHARMS

Learn More

Dosage and Administration

TABLET ORAL; FOR SUSPENSION ORAL

Specification

100MG (TABLET;ORAL); 25MG/ML (FOR SUSPENSION;ORAL)

Indication

Ojemda® is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

Use

Instructions for Use

API

TOVORAFENIB

API Structure

We Supply

TOVORAFENIB

Drug Patent

Patent No	Expiration Date
10426782	2035/6/23
8293752	2031/8/4

API Patent

Patent No	Expiration Date
8293752	2031/8/4

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION